Access the full text.
Sign up today, get DeepDyve free for 14 days.
A study of the efficacy and safety of upadacitinib (ABT‐494) in subjects with moderately to severely active Crohn's disease who have inadequately responded to or are intolerant to conventional therapies but have not failed biologic therapy
Amit Khatri, B. Klünder, P. Peloso, A. Othman (2018)
Exposure–response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritisRheumatology, 58
(2008)
A tutorial on visual predictive checks. Page 17. Abstract 1434
A study to evaluate ABT-494 in adult subjects with moderate to severe atopic dermatitis
A study evaluating the safety and efficacy of upadacitinib in subjects with active ankylosing spondylitis (SELECT Axis 1)
K. Ghoreschi, A. Laurence, J. O’Shea (2009)
Janus kinases in immune cell signalingImmunological Reviews, 228
(2018)
A phase 3, randomized, controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX‐naïve patients with active rheumatoid arthritis [abstract]
M. Genovese, R. Fleischmann, B. Combe, S. Hall, A. Rubbert-Roth, Ying Zhang, Yijie Zhou, M. Mohamed, S. Meerwein, A. Pangan (2018)
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trialThe Lancet, 391
J. O’Shea, A. Kontzias, K. Yamaoka, Yoshiya Tanaka, A. Laurence (2013)
Janus kinase inhibitors in autoimmune diseasesAnnals of the Rheumatic Diseases, 72
(2019)
Results of a Phase 3, Double-Blind, Randomized Controlled Trial
O. Dogar (2021)
in with a randomised, double-blind, placebo-controlled phase 3 trial
N. Holford (2005)
The Visual Predictive Check Superiority to Standard Diagnostic (Rorschach) Plots
A study of the efficacy and safety of upadacitinib (ABT-494) in subjects with moderately to severely active Crohn's disease who have inadequately responded to or are intolerant to biologic therapy
J. Kremer, P. Emery, H. Camp, A. Friedman, Li Wang, A. Othman, N. Khan, A. Pangan, S. Jungerwirth, E. Keystone (2016)
A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor TherapyArthritis & Rheumatology (Hoboken, N.j.), 68
A phase 3 study to compare ABT‐494 to abatacept in subjects with rheumatoid arthritis on stable dose of conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs) who have an inadequate response or intolerance to biologic DMARDs (SELECT‐CHOICE)
M. Genovese, J. Smolen, M. Weinblatt, G. Burmester, S. Meerwein, H. Camp, Li Wang, A. Othman, N. Khan, A. Pangan, S. Jungerwirth (2016)
Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to MethotrexateArthritis & Rheumatology (Hoboken, N.j.), 68
A study to evaluate the safety and efficacy of ABT‐494 for induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis
M. Mohamed, J. Zeng, P. Marroum, I. Song, A. Othman (2018)
Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended‐Release Formulation Utilized in Rheumatoid Arthritis Phase 3 TrialsClinical Pharmacology in Drug Development, 8
A study to evaluate the safety and efficacy of upadacitinib in participants with giant cell arteritis
A study comparing ABT‐494 to placebo in participants with active psoriatic arthritis who have a history of inadequate response to at least one biologic disease modifying anti‐rheumatic drug (SELECT ‐ PsA 2)
(2018)
Results of a Phase 3, Double-Blind, Randomized Controlled Trial [abstract
Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double-Blind
A study comparing ABT‐494 to placebo and to adalimumab in participants with psoriatic arthritis who have an inadequate response to at least one non‐biologic disease modifying anti‐rheumatic drug (SELECT ‐ PsA 1)
R. Fleischmann, A. Pangan, I. Song, E. Mysler, L. Bessette, C. Peterfy, P. Durez, A. Ostor, Yihan Li, Yijie Zhou, A. Othman, M. Genovese (2019)
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled TrialArthritis & Rheumatology, 71
G. Burmester, J. Kremer, F. Bosch, A. Kivitz, L. Bessette, Yihan Li, Yijie Zhou, A. Othman, A. Pangan, H. Camp (2018)
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 391
A tutorial on visual predictive checks
M. Lovern, M. Sargentini‐Maier, C. Otoul, J. Watelet (2009)
Population pharmacokinetic and pharmacodynamic analysis in allergic diseasesDrug Metabolism Reviews, 41
A phase 3, randomized, controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX-naïve patients with active rheumatoid arthritis
(2017)
what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann
B. Klünder, M. Mohamed, A. Othman (2017)
Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical TrialsClinical Pharmacokinetics, 57
(2018)
a double-blind, randomised controlled phase 3 trial
Available from https ://clini caltr ials.gov/ct2/show/NCT03 34583 6?term=NCT03 34583 6&rank=1
P. Norman (2014)
Selective JAK inhibitors in development for rheumatoid arthritisExpert Opinion on Investigational Drugs, 23
B. Lacroix, M. Karlsson, L. Friberg (2014)
Simultaneous Exposure–Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab PegolCPT: Pharmacometrics & Systems Pharmacology, 3
(2018)
analyses of phase I and II clinical trials
K. Baker, J. Isaacs (2017)
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis?Annals of the Rheumatic Diseases, 77
M. Mohamed, H. Camp, P. Jiang, R. Padley, A. Asatryan, A. Othman (2016)
Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid ArthritisClinical Pharmacokinetics, 55
Clinical Pharmacology & Therapeutics – Wiley
Published: Dec 1, 2019
You can share this free article with as many people as you like with the url below! We hope you enjoy this feature!
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.